SPRB Live signaler | Maksimer profitt med Getagraph.com

SELG 106841 min ago

@ $4.51

Utstedt: 13 feb 2024 @ 21:35

Avkastning: -84.48%

Forrige signal: feb 13 - 15:31

Forrige signal: Kjøp

Avkastning: 4.64 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	210 515
Gjennomsnittsvolum	1.35M
Markedsverdi	28.80M
EPS	$0 ( 2024-03-21 )
Neste inntjeningsdato	( $-0.320 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.560
ATR14	$0.00200 (0.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Novo Holdings A/s	Sell	465 021	COMMON STOCK
2024-03-18	Novo Holdings A/s	Sell	842 020	COMMON STOCK
2024-03-19	Novo Holdings A/s	Sell	593 000	COMMON STOCK
2024-03-20	Novo Holdings A/s	Sell	359 979	COMMON STOCK
2024-03-14	Novo Holdings A/s	Sell	1 912 316	COMMON STOCK

INSIDER POWER
2.74
Last 98 transactions
Buy: 11 294 782 \| Sell: 4 967 660

Volum Korrelasjon

Lang: -0.05 (neutral)

Kort: -0.92 (very strong negative)

Signal:(40.591) Neutral

Spruce Biosciences, Inc. Korrelasjon

10 Mest positive korrelasjoner
DYNT	0.967
DGLY	0.954
FTFT	0.94
SLNO	0.94
SYKE	0.929
CVV	0.927
LIVE	0.925
CSWI	0.923
FELE	0.922
IPHA	0.921

10 Mest negative korrelasjoner
MTEX	-0.906
LCAP	-0.905
AHPI	-0.899
NAKD	-0.887
PROC	-0.883
LAWS	-0.88
VERA	-0.872
GRPH	-0.869
OP	-0.868
TRIT	-0.868

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Spruce Biosciences, Inc. Korrelasjon - Valuta/Råvare

0.00
( neutral )

0.51
( weak )

0.00
( neutral )

-0.54
( weak negative )

Spruce Biosciences, Inc. Økonomi

Annual	2023
Omsetning:	$10.09M
Bruttogevinst:	$10.02M (99.31 %)
EPS:	$-1.240

FY	2023
Omsetning:	$10.09M
Bruttogevinst:	$10.02M (99.31 %)
EPS:	$-1.240

FY	2022
Omsetning:	$0
Bruttogevinst:	$-429 000 (0.00 %)
EPS:	$-1.920

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.813

Financial Reports:

No articles found.

Spruce Biosciences, Inc.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.